Phase I trial of paclitaxel, doxorubicin, and carboplatin (TAC) for the treatment of endometrial cancer

International Journal of Gynecological Cancer

Volumn 17, Issue 1, 2007, Pages 210-214

  Shimada, M ^a   Kigawa, J ^a   Terakawa, N ^a   Yoshizaki, A ^b   Shoji, T ^b   Suzuki, M ^c   Hatae, M ^d   Tsuda, H ^e   Ohwada, M ^c   Sugiyama, T ^b  

^a TOTTORI UNIVERSITY   (Japan)

^b IWATE MEDICAL UNIVERSITY   (Japan)

^c JICHI MEDICAL UNIVERSITY   (Japan)

^d Kagoshima City Hospital   (Japan)

^e OSAKA CITY GENERAL HOSPITAL   (Japan)

Author keywords

Chemotherapy; Endometrial cancer; TAC

Indexed keywords

CARBOPLATIN; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ADULT; AGED; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG DOSE ESCALATION; DRUG INFUSION; ENDOMETRIUM CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN TISSUE; ILEUS; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OPTIMAL DRUG DOSE; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; PACLITAXEL;

EID: 33846813876     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.00801.x     Document Type: Article

References (14)

1. Thigpen JT, Blessing JA, Homesley HD, Creasman WT, Sutton G. Phase II trial of cisplatin as first line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 1989;33:68-70.
2. Thigpen JT, Brady MF, Homesley HD et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2004;22:3902-8.
3. Randall ME, Brunetto G, Muss H et al. Whole abdominal radiotherapy versus combination doxorubicin-cisplatin chemotherapy in advanced endometrial carcinoma: a randomized phase III trial of the Gynecologic Oncology Group [abstract]. Proc Am Soc Clin Oncol 2003;22:2. Abstract 3.
4. Elit L, Hirte H. Current status and future innovations of hormonal agents, chemotherapy and investigation agents in endometrial cancer. Curr Opin Rep 1999;1:47-53.
5. Cohen CJ. Cytotoxic chemotherapy for patients with endometrial carcinoma. Clin Obstet Gynaecol 1986;13:811-24.
6. Thigpen JT, Blessing JA, DiSaia PJ, Yordan E, Carson LF, Evers C. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 1994;12:1408-14.
7. European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomized study (55872) by the EORTC Gynecological Cancer Group. Ann Oncol 2003;14:441-8.
8. Lincoln S, Blessing JA, Lee RB, Rocereto TF. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 2003;88:277-81.
9. Fleming GF, Brunetto VL, Cella D et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2004;22:2159-66.
10. Burke TW, Munkarah A, Kavanagh JJ et al. Treatment of advanced or recurrent endometrial carcinoma with single-agent CBDCA. Gynecol Oncol 1993;51:397-400.
11. Thigpen JT, Vance RB, Khansur T. The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cervix. Semin Oncol 1995;22:67-75.
12. Weber B, Mayer F, Bougnoux P et al. What is the best chemotherapy regimen in recurrent or advanced endometrial carcinoma? Preliminary results [abstract]. Am Soc Clin Oncol 2003;22:453. Abstract 1819.
13. Moreira A, Lobato R, Morais J et al. Influence of the interval between the administration of doxorubicin and paclitaxel on the pharmacokinetics of these drugs in patients with locally advanced breast cancer. Cancer Chemother Pharmacol 2001;48:333-7.
14. Sagae S, Udagawa Y, Susumu N, Niwa K, Kudo R, Nozawa S. JGOG2033: randomized phase III trial of whole pelvic radiotherapy vs cisplatin-based chemotherapy in patients with intermediate risk endometrial carcinoma [abstract]. Am Soc Clin Oncol 2005;23:455s. Abstract 5002.